pipette
ENEnglish

Rewiring dendritic cell function with CLEC9A and DEC205 CARs

Congyi Niu, Xiaoqiu Dai, He Gao, H Zhang, Yunju Ma, Hui Wang, Zhen Xiao, Yingxi Xu, Sudan He, Sudan He, Xiaowen Tang, Peng Lin, Peng Lin, Mikaël J. Pittet, Lianjun Zhang, Chen Wang

Revista con revisión por paresAfirmaciones fuertes, leer con cuidadoUso en el mundo real

En palabras de los autores

Abstract Dendritic cells (DCs) are central orchestrators of anti-tumor immunity, yet their therapeutic utility has been limited by dysfunction and insufficient activation within solid tumors. Here, we report chimeric antigen receptor-engineered DCs (CAR-DCs) that potently prime T cells and reprogram the tumor microenvironment. We identify the intracellular domains of CLEC9A or DEC205 as essential for functional CAR-DC activity, enabling enhanced antigen uptake, cross-presentation, and robust cytokine production that drive strong T cell expansion and effector differentiation. Mechanistically, CARs incorporating CLEC9A or DEC205 intracellular domains triggered SYK phosphorylation and downstream signaling pathways. In both murine and humanized models, CAR-DC therapy suppressed tumor growth and promoted expansion of tumor-reactive T cells. These findings establish CAR-DCs as a scalable and clinically translatable platform for next-generation solid tumor immunotherapy.

Resultado principalEl resumen no menciona limitaciones.

Apareció: domingo, 15 de noviembre. Nature Immunology. Revista con revisión por pares.

DOI: 10.1038/s41590-026-02711-3